Targeting novel inhibitory receptors in cancer immunotherapy

Area of Science:

• Immunology
• Oncology
• Cancer Immunotherapy

Background:

• T cells are crucial for tumor regression, but chronic antigen exposure leads to dysfunction or exhaustion, hindering anti-tumor responses.
• Immune checkpoint inhibitory receptors, such as PD-1 and CTLA-4, are upregulated on tumor-infiltrating lymphocytes, suppressing T cell function.
• Current immunotherapies targeting PD-1/PD-L1 and CTLA-4 show efficacy but have limitations, including non-response and adverse events.

Purpose of the Study:

• To review preclinical and clinical evidence for novel inhibitory receptor pathways in cancer immunotherapy.
• To explore the role of T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) and the TIGIT/CD226/CD96/CD112R axis in tumor-induced T cell dysfunction.
• To identify potential new therapeutic targets for overcoming resistance to current cancer immunotherapies.

Main Methods:

• Review of preclinical studies investigating T cell dysfunction in the tumor microenvironment.
• Analysis of clinical trial data for immunotherapies targeting inhibitory receptor pathways.
• Examination of the mechanisms by which TIM-3 and TIGIT/CD226/CD96/CD112R influence T cell function in cancer.

Main Results:

• Upregulation of immune checkpoint receptors contributes significantly to T cell dysfunction in various cancers.
• TIM-3 and the TIGIT/CD226/CD96/CD112R pathway are implicated as key drivers of T cell exhaustion.
• Targeting these novel pathways holds promise for enhancing anti-tumor immunity.

Conclusions:

• Novel inhibitory receptor pathways, including TIM-3 and TIGIT, represent promising targets for next-generation cancer immunotherapies.
• Overcoming T cell dysfunction via these non-redundant pathways may improve treatment efficacy and reduce toxicity.
• Further research into TIM-3 and TIGIT-targeted therapies is warranted to enhance cancer treatment outcomes.